List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 82 studies with search of: "Daclizumab"
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Completed Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
Condition: Renal Transplantation
Interventions: Drug: Thymoglobulin (ATG);   Drug: Daclizumab
2 Recruiting A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
Conditions: Aplastic Anemia;   Pure Red Cell Aplasia;   Diamond Blackfan Anemia
Interventions: Drug: Daclizumab;   Drug: Daclizumab (Zenapax)
3 Recruiting Safety and Efficacy Study of Thymoglobulin Versus Zenapax
Condition: End Stage Renal Disease
Interventions: Drug: Rabbit Antithymocyte globulin;   Drug: Daclizumab
4 Completed ANTI-TAC THERAPY FOR UVEITIS
Condition: Uveitis
Intervention: Drug: Daclizumab (Zenapax)
5 Completed Human Anti-Tac (Daclizumab) to Treat JIA-Associated Uveitis
Conditions: Anterior Uveitis;   Arthritis, Juvenile Idiopathic;   Daclizumab;   Iritis;   Immunosuppression
Intervention: Drug: HAT, Daclizumab
6 Completed To Study the Effects of CD25 and Low Dose Cyclosporin in the Treatment of Active Psoriasis Vulgaris
Condition: Psoriasis
Interventions: Drug: Daclizumab;   Drug: Cyclosporine;   Drug: cyclosporine and Daclizumab
7 Completed Study of Daclizumab in Patients With Chronic, Persistent Asthma
Condition: Asthma
Intervention: Drug: Daclizumab
8 Completed Daclizumab Injections to Treat Non-Infectious Sight-Threatening Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
9 Completed Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Intervention: Drug: Daclizumab
10 Completed Daclizumab to Treat Non-Infectious Sight-Threatening Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
11 Completed Daclizumab and Sirolimus to Treat Uveitis
Condition: Uveitis
Intervention: Drug: Daclizumab
12 Completed Combination Daclizumab/Denileukin Diftitox to Treat Uveitis
Condition: Non-Infectious Intermediate and Posterior Uveitis
Intervention: Drug: Daclizumab
13 Completed MMF, Daclizumab and Corticosteroids as Mainstay Immunosuppression in Renal Transplant Patients
Condition: Kidney Transplantation
Intervention: Drug: daclizumab
14 Completed To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris
Condition: Psoriasis
Interventions: Drug: Daclizumab;   Device: NB-UVB
15 Completed A Trial of Two Daclizumab Dosing Strategies Vs. No Induction Treatment With Tacrolimus, MMF, & Steroids for the Prevention of Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Condition: Acute Allograft Rejection in Simultaneous Kidney/Pancreas Transplant Recipients
Intervention: Drug: Daclizumab
16 Recruiting Safety and Efficacy Extension Study of Daclizumab HYP to Treat Relapsing-Remitting Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Daclizumab HYP;   Drug: Daclizumab HYP
17 Completed Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
18 Recruiting Anti Cytokine Combination Therapy With Daclizumab and Infliximab for Treatment of Steroid Refractory Acute GVHD
Condition: Graft vs Host Disease
Intervention: Drug: daclizumab, infliximab
19 Active, not recruiting Daclizumab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
Condition: Brain and Central Nervous System Tumors
Interventions: Biological: RNA-loaded dendritic cell vaccine;   Biological: cytomegalovirus pp65-specific cytotoxic T lymphocytes;   Biological: daclizumab;   Biological: therapeutic autologous dendritic cells;   Biological: therapeutic autologous lymphocytes;   Drug: imiquimod;   Drug: temozolomide;   Procedure: radionuclide imaging;   Procedure: single photon emission computed tomography;   Radiation: stereotactic body radiation therapy
20 Active, not recruiting Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease
Condition: Graft Versus Host Disease
Interventions: Biological: daclizumab;   Drug: methylprednisolone

Previous Page Studies Shown (1-20) Next Page (21-40)
Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
  RSS Feed for studies found by your search that were received in the last 14 days
  Download Options




U.S. National Library of Medicine,  Contact Help Desk
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services